

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



AIM Vaccine Co., Ltd.

艾美疫苗股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 06660)

RE-DESIGNATION OF DIRECTORS

The board (the “**Board**”) of directors (the “**Directors**”) of AIM Vaccine Co., Ltd. (the “**Company**”) is pleased to announce that Mr. Jie ZHOU and Mr. Xin ZHOU have been re-designated from non-executive Directors to executive Directors, and appointed as executive presidents of the Company, with effect from August 29, 2024 until the expiration of the term of office of the current session of the Board (the “**Re-designation**”).

Upon the Re-designation, Mr. Jie ZHOU and Mr. Xin ZHOU ceased to be members of the audit committee of the Board.

In respect of the Re-designation, the Company will enter into new service contracts with Mr. Jie ZHOU and Mr. Xin ZHOU. Mr. Jie ZHOU and Mr. Xin ZHOU will not receive any director's fee from the Company during their term but will receive remuneration based on their management positions with the Company. Their remuneration arrangement will be determined with reference to their experience, duties, responsibilities and the Company's remuneration policy. The Company will disclose their remuneration as Directors in its annual report each year.

Biographical details of Mr. Xin ZHOU and Mr. Jie ZHOU

Mr. Jie ZHOU (周杰), aged 61, has served as a Director since May 2015, was re-designated as a non-executive Director on June 9, 2021, and was further re-designated as an executive Director on August 29, 2024. Mr. Jie ZHOU served as the manager of the Company from December 2015 to December 2016 and the chairman of the Board from December 2016 to September 2020. He was appointed as an executive president of the Company on August 29, 2024.

Mr. Jie ZHOU has served as a director of Tibet Tianxia Holdings Group Co., Ltd. (西藏天下控股集團股份有限公司) since May 2012. From May 2013 to May 2017, he has held various management positions at Liaoning Green Biological Pharmaceutical Group Co., Ltd. (遼寧格林生物藥業集團股份有限公司), including chairman, director and manager. In terms of his investment experiences, Mr. Jie ZHOU directly owns Jiuding Cellular Therapy Industry (Liaoning) Co., Ltd. (九鼎細胞治療產業(遼寧)有限公司), a company which has not commenced business operation, as to 99.99%, which in turn invests in Green Biological Group Co., Ltd. (格林生物集團有限公司).

Mr. Jie ZHOU received his master's degree in business administration from Cheung Kong Graduate School of Business (長江商學院) in September 2013. He is the brother of Mr. Yan ZHOU, who is an executive Director, the chairman of the Board and CEO and the controlling shareholder of the Company, and Mr. Xin ZHOU, who is an executive Director, the executive vice chairman of the Board and an executive president of the Company.

Mr. Xin ZHOU (周欣), aged 56, has served as a Director since May 2013, was re-designated as a non-executive Director on June 9, 2021, and was further re-designated as an executive Director on August 29, 2024. He has served as the executive vice chairman of the Board since February 29, 2024, and was appointed as an executive president of the Company on August 29, 2024.

Prior to joining the Company, Mr. Xin ZHOU was an executive director and manager at Tibet Silicon Valley Angel Venture Capital Co., Ltd. (西藏硅谷天使創業投資有限公司) from June 2010 to December 2020. In terms of his investment experiences, Mr. Xin ZHOU directly owns Woye Biotechnology (Liaoning) Co., Ltd. (沃野生物技術(遼寧)有限公司), a company which has not commenced business operation, as to 99.99%, which in turn invests in Green Biological Group Co., Ltd. (格林生物集團有限公司).

Mr. Xin ZHOU studied for an executive master of business administration from Cheung Kong Graduate School of Business (長江商學院) in 2012 and received an executive master of business administration from Tsinghua University (清華大學) in June 2022. He is the brother of Mr. Yan ZHOU, who is an executive Director, the chairman of the Board and CEO and the controlling shareholder of the Company, and Mr. Jie ZHOU, who is an executive Director and executive president of the Company.

As of the date of this announcement, Mr. Jie ZHOU has an interest in 40,000,000 domestic shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “SFO”), and Mr. Xin ZHOU has an interest in 40,000,000 domestic shares of the Company within the meaning of Part XV of the SFO.

As of the date of this announcement, save as disclosed above, each of Mr. Jie ZHOU and Mr. Xin ZHOU: (i) has not held any other positions in the Company or its subsidiaries; (ii) has not held any other directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas during the last three years; (iii) does not have any other major appointments and professional qualifications; (iv) does not have any relationship with any directors, supervisors, senior management or substantial or controlling shareholders of the Company; and (v) does not have any interest in the shares of the Company which are within the meaning of Part XV of the SFO.

Save as disclosed in this announcement, there is no information in relation to the Re-designation that needs to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Listing Rules, and there is no other matter in relation to the Re-designation that needs to be brought to the attention of the shareholders of the Company.

By order of the Board
AIM Vaccine Co., Ltd.
Mr. Yan ZHOU
Chairman of the Board,
Executive Director and Chief Executive Officer

Hong Kong, August 29, 2024

As at the date of this announcement, the Board comprises Mr. Yan ZHOU, Mr. Xin ZHOU, Mr. Wen GUAN, Mr. Shaojun JIA and Mr. Jie ZHOU as executive Directors; Mr. Jichen ZHAO and Ms. Aijun WANG as non-executive Directors; and Professor Ker Wei PEI, Mr. Hui OUYANG, Ms. Jie WEN and Mr. Xiaoguang GUO as independent non-executive Directors.